Deciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics
- PMID: 33914273
- DOI: 10.1007/s13402-021-00611-2
Deciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics
Abstract
Background: The transition of a primary tumour to metastatic progression is driven by dynamic molecular changes, including genetic and epigenetic alterations. The metastatic cascade involves bidirectional interactions among extracellular and intracellular components leading to disintegration of cellular junctions, cytoskeleton reorganization and epithelial to mesenchymal transition. These events promote metastasis by reprogramming the primary cancer cell's molecular framework, enabling them to cause local invasion, anchorage-independent survival, cell death and immune resistance, extravasation and colonization of distant organs. Metastasis follows a site-specific pattern that is still poorly understood at the molecular level. Although various drugs have been tested clinically across different metastatic cancer types, it has remained difficult to develop efficacious therapeutics due to complex molecular layers involved in metastasis as well as experimental limitations.
Conclusions: In this review, a systemic evaluation of the molecular mechanisms of metastasis is outlined and the potential molecular components and their status as therapeutic targets and the associated pre-clinical and clinical agents available or under investigations are discussed. Integrative methods like pan-cancer data analysis, which can provide clinical insights into both targets and treatment decisions and help in the identification of crucial components driving metastasis such as mutational profiles, gene signatures, associated pathways, site specificities and disease-gene phenotypes, are discussed. A multi-level data integration of the metastasis signatures across multiple primary and metastatic cancer types may facilitate the development of precision medicine and open up new opportunities for future therapies.
Keywords: Circulating tumour cells; Epithelial‐mesenchymal transition; Metastasis; Pan‐cancer analysis; Precision medicine; Secondary tumour.
© 2021. Springer Nature Switzerland AG.
Similar articles
-
Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis.Anticancer Res. 2016 Feb;36(2):523-32. Anticancer Res. 2016. PMID: 26851006
-
Molecular insights into tumour metastasis: tracing the dominant events.J Pathol. 2017 Apr;241(5):567-577. doi: 10.1002/path.4871. Epub 2017 Mar 7. J Pathol. 2017. PMID: 28035672 Review.
-
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.Clin Cancer Res. 2016 Feb 1;22(3):609-20. doi: 10.1158/1078-0432.CCR-15-0876. Epub 2015 Sep 29. Clin Cancer Res. 2016. PMID: 26420858 Free PMC article.
-
Long non-coding RNA regulation of epithelial-mesenchymal transition in cancer metastasis.Cell Death Dis. 2016 Jun 9;7(6):e2254. doi: 10.1038/cddis.2016.149. Cell Death Dis. 2016. PMID: 27277676 Free PMC article. Review.
-
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets.Mol Cancer. 2024 Jun 7;23(1):122. doi: 10.1186/s12943-024-02033-8. Mol Cancer. 2024. PMID: 38844984 Free PMC article. Review.
Cited by
-
Biglycan Promotes Cancer Stem Cell Properties, NFκB Signaling and Metastatic Potential in Breast Cancer Cells.Cancers (Basel). 2022 Jan 17;14(2):455. doi: 10.3390/cancers14020455. Cancers (Basel). 2022. PMID: 35053617 Free PMC article.
-
Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer.Cancers (Basel). 2021 Sep 6;13(17):4486. doi: 10.3390/cancers13174486. Cancers (Basel). 2021. PMID: 34503296 Free PMC article. Review.
-
An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.Eur J Med Res. 2023 Mar 15;28(1):123. doi: 10.1186/s40001-023-01091-w. Eur J Med Res. 2023. PMID: 36918943 Free PMC article.
-
Natural Products as New Approaches for Treating Bladder Cancer: From Traditional Medicine to Novel Drug Discovery.Pharmaceutics. 2023 Mar 31;15(4):1117. doi: 10.3390/pharmaceutics15041117. Pharmaceutics. 2023. PMID: 37111603 Free PMC article. Review.
References
-
- A. Chatterjee, E.J. Rodger, M.R. Eccles, Epigenetic drivers of tumourigenesis and cancer metastasis. Semin. Cancer Biol. 51, 149–159 (2018). https://doi.org/10.1016/j.semcancer.2017.08.004 - DOI - PubMed
-
- D.F. Quail, J.A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013). https://doi.org/10.1038/nm.3394 - DOI - PubMed - PMC
-
- D.R. Welch, D.R. Hurst, Defining the hallmarks of metastasis. Cancer Res. 79, 3011–3027 (2019). https://doi.org/10.1158/0008-5472.can-19-0458 - DOI - PubMed - PMC
-
- M. Teeuwssen, R. Fodde, Cell heterogeneity and phenotypic plasticity in metastasis formation: The case of colon cancer. Cancers 11, 1368 (2019). https://doi.org/10.3390/cancers11091368 - DOI - PMC
-
- D.A. Lawson, K. Kessenbrock, R.T. Davis, N. Pervolarakis, Z. Werb, Tumour heterogeneity and metastasis at single-cell resolution. Nat. Cell Biol. 20, 1349–1360 (2018). https://doi.org/10.1038/s41556-018-0236-7 - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical